Company
ImpediMed
ASX:IPD
ImpediMed is a leading global medical technology company that designs and manufactures medical devices that employ bioimpedance spectroscopy (BIS) technology for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients. The company consistently drives innovation by directing its primary efforts toward addressing the specific challenges and devastating burden of secondary lymphedema with a focus on breast cancer-related lymphedema (BCRL).
18 stories
ImpediMed enrols first patient in chronic heart failure trial
The company is planning its European launch in calendar year 2017
Updater Inc to reveal material results
The halt will remain in place until Wednesday 28th June 2017.
ImpediMed begins lymphoedema study using its health device
The aim is to detect lymphoedema at the earliest possible point.